The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease.

[1]  R. Cody,et al.  The integrated effects of angiotensin II. , 1997, The American journal of cardiology.

[2]  P. Binkley,et al.  Early left ventricular dysfunction elicits activation of sympathetic drive and attenuation of parasympathetic tone in the paced canine model of congestive heart failure. , 1995, Circulation.

[3]  J. Laragh.  Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). , 1995, Journal of human hypertension.

[4]  A L Mark,et al.  Sympathetic dysregulation in heart failure: Mechanisms and therapy , 1995, Clinical cardiology.

[5]  L. Aiello,et al.  Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. , 1995, The Journal of clinical investigation.

[6]  J. Cohn.  Plasma norepinephrine and mortality , 1995, Clinical cardiology.

[7]  M. Metra,et al.  Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.

[8]  R. Bain,et al.  Effects of vesnarinone on morbidity and mortality in patients with heart failure , 1993 .

[9]  M. Packer,et al.  The search for the ideal positive inotropic agent. , 1993, The New England journal of medicine.

[10]  J. Ollivier,et al.  Prospects for cardioreparation. , 1992, The American journal of cardiology.

[11]  J. Laragh,et al.  Cardiac secretion of atrial natriuretic factor with exercise in chronic congestive heart failure patients. , 1992, Journal of applied physiology.

[12]  L. Lind,et al.  Metabolic cardiovascular risk factors and the renin-aldosterone system in essential hypertension. , 1992, Journal of human hypertension.

[13]  F. Bühler,et al.  Blood Pressure Control by the Renin‐Angiotensin System in Normotensive Subjects: Assessment by Angiotensin Converting Enzyme and Renin Inhibition , 1992, Circulation.

[14]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[15]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[16]  P. Broadhurst,et al.  Value of carvedilol in congestive heart failure secondary to coronary artery disease. , 1990, The American journal of cardiology.

[17]  J. Cohn,et al.  Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  D. Ferguson,et al.  Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. , 1989, Circulation.

[19]  R. Cody.  Neurohormonal influences in the pathogenesis of congestive heart failure. , 1989, Cardiology clinics.

[20]  C. Dollery,et al.  Drug treatment of heart failure. , 1985, British heart journal.

[21]  R. Gunnar,et al.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. , 1985, Circulation.

[22]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[23]  J. Laragh,et al.  Mechanisms Governing the Postural Response and Baroreceptor Abnormalities in Chronic Congestive Heart Failure: Effects of Acute and Long‐term Converting‐enzyme Inhibition , 1982, Circulation.

[24]  J. Laragh,et al.  The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril). , 1982, The American journal of cardiology.

[25]  J. Laragh,et al.  Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril. , 1982, The American journal of medicine.

[26]  J. A. Thomas,et al.  Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.

[27]  J. Laragh,et al.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. , 1972, The New England journal of medicine.

[28]  E. Braunwald,et al.  CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. , 1965, The American journal of medicine.

[29]  M. Esler.  Sympathetic Nervous System: Contribution to Human Hypertension and Related Cardiovascular Diseases , 1995, Journal of cardiovascular pharmacology.

[30]  S. Kjeldsen,et al.  The Sympathetic Nervous System May Modulate the Metabolic Cardiovascular Syndrome in Essential Hypertension , 1992, Journal of cardiovascular pharmacology.

[31]  J. Corbett,et al.  Effects of bucindolol on neurohormonal activation in congestive heart failure. , 1991, The American journal of cardiology.

[32]  M. Peach,et al.  The angiotensin II receptor and the actions of angiotensin II. , 1990, Journal of cardiovascular pharmacology.

[33]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[34]  V. Convertino,et al.  Plasma volume, osmolality, vasopressin, and renin activity during graded exercise in man. , 1981, Journal of applied physiology: respiratory, environmental and exercise physiology.